Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	179.13B
Revenue (ttm)	2.55B +37.4%
Net Income	-13.83B
EPS	-2,392.44
Shares Out	6.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,744
Average Volume	115,210
Open	26,600
Previous Close	26,250
Day's Range	25,800 - 27,850
52-Week Range	23,000 - 52,000
Beta	n/a
RSI	44.16
Earnings Date	Mar 27, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.